查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
MicroRNAs (miRNAs) 的全球市場-2022-2029
市場調查報告書
商品編碼
1129281

MicroRNAs (miRNAs) 的全球市場-2022-2029

Global MicroRNA Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場動態

新興國家的 COVID-19 mRNA 疫苗開發預計將推動市場增長。

由 SARS-CoV-2 引起的新型冠狀病毒病 (COVID-19) 已導致全球 399,600,607 例病例和 5,757,562 人死亡。 COVID-19 對世界各地的人們構成嚴重的健康風險。世界衛生組織 (WHO) 已宣布 COVID-19 大流行為全球突發公共衛生事件。接種疫苗是預防流行病傳播、挽救生命和保護人民健康的最成功和最具成本效益的方法。已經使用多種方法開發了 COVID-19 疫苗。其中，COVID-19信使RNA（mRNA）疫苗具有適用性廣、開發週期短、易於產業化、製造工藝簡單、對新亞種反應能力強、誘導免疫反應更強等優點。能力，關注度越來越高。

此外，研究人員長期以來一直在探索使用 mRNA 疫苗治療癌症。近十年來，基於 mRNA 的癌症治療疫苗已經在適度的研究中進行了調查，並產生了一些有希望的早期發現。例如，輝瑞生物技術公司和 Moderna 公司利用他們在生產 mRNA 癌症疫苗方面的經驗來製造冠狀病毒疫苗。一些研究人員希望 COVID-19 mRNA 疫苗的功效將有助於推進癌症治療 mRNA 疫苗的臨床研究。因此，從上述陳述來看，預計市場將在預測期內受到驅動。

限制

由於 microRNA (miRNA) 試劑盒成本高、耗時長，因此對 miRNA 靶點的準確計算預測是當務之急，在預測期間將解決 miRNA 的安全性和毒性問題。阻礙市場。

行業分析

MicroRNA (miRNA) Market 提供基於供應鏈分析、價格分析等各種行業因素的市場深度分析。

COVID-19 影響分析

COVID-19 大流行對醫療保健系統和市場產生了適度影響。 MicroRNAs (miRNAs) 在與病毒基因組的 3'-UTR 結合後抑制病毒翻譯，或與 SARS-CoV-2 受體、結構或非結構蛋白結合，而不影響人類基因表達。您可以靶向。例如，ID02510.3p-miRNA、ID00448.3pmiRNA、miRNA 3154、miRNA 7114-5p、miRNA 5197-3p、ID02750.3p-miRNA、ID01851.5p-miRNA與SARS-CoV-2基因組和轉錄後結合通過抑製表達來抑制 COVID-19 的發作Nersisyan 等人將 miR-21-3p、miR-195-5p、miR-16-5p、miR-3065-5p、miR-424-5p 和 miR-424-5p 鑑定為可以直接與病毒結合的 miRNA基因組和調節所有人類冠狀病毒。鑑定出六種5p，miR-421。與人類冠狀病毒基因組結合最好的是 miR-21-3p。因此，COVID-19 的日益流行增加了對有效療法的需求，推動了對下一代測序技術和 miRNA 測序儀的需求。

另一方面，大流行會破壞供應鍊和流程。許多公司將轉移到其他地區以確保產品可用性並保護其供應鏈。因此，從上述陳述來看，預計市場將受到影響，並隨著經濟活動的恢復而迅速獲得牽引力。

此報告將提供對大約 45 多個市場數據表、40 多個數字和 180 頁的訪問。

內容

第一章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第 4 章市場動態

  • 市場影響因素
    • 驅動程序
      • 新興國家的 COVID-19 mRNA 疫苗開發預計將成為市場增長的驅動力。
    • 限制因素
      • 與 microRNA (miRNA) 試劑盒相關的高成本預計會阻礙市場增長。
    • 機會
    • 影響分析

第五章行業分析

  • 供應鏈分析
  • 定價分析
  • 未滿足的需求分析
  • 管道分析

第 6 章 COVID-19 分析

  • COVID-19 的市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按產品分類

  • 設備/套件
  • 消耗品
  • 試劑
  • 其他

第 8 章技術

  • 實時聚合□鍊式反應
  • 微陣列
  • 二代測序 (NGS)
  • 免疫測定
  • 其他

第 9 章。按應用程序

  • 癌症
  • 感染
  • 免疫性疾病
  • 心血管疾病
  • 神經系統疾病
  • 其他

第 10 章，最終用戶

  • 學術和研究機構
  • 生物製藥公司
  • 委託研究機構
  • 診斷中心
  • 其他

第 11 章按地區劃分

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 12 章競爭格局

  • 主要發展和戰略
  • 公司份額分析
  • 產品基準
  • 值得關注的重點公司列表

第 13 章公司簡介

  • Qiagen N.V.
    • 公司簡介
    • 產品組合和描述
    • 主要亮點
    • 財務摘要
  • Illumina, Inc.
  • Takara Bio, Inc
  • PerkinElmer, Inc.
  • Thermo Fisher Scientific
  • Bio-Rad Laboratories Inc.
  • Abcam Plc
  • GeneCopoeia, Inc.
  • System Biosciences LLC
  • Miltenyi Biotec

第14章 世界miRNA市場-DataM

簡介目錄
Product Code: DMBT5827

Market Overview

MicroRNA Market size was valued at US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 19.3 % during the forecast period (2022-2029).

MicroRNAs (or miRNAs) are a new class of tiny, non-coding endogenous RNAs that control gene expression by targeting mRNAs for destruction or translational suppression. Their discovery expanded the understanding of complicated gene regulation networks in humans and animals. miRNAs influence many areas of development and physiology. Understanding its biological role is thus becoming increasingly crucial. miRNA expression analysis may provide useful information because deregulation of its function can lead to human disorders such as cancer, cardiovascular and metabolic diseases, liver problems, and immunological dysfunction.

Market Dynamics

Advances in the COVID-19 mRNA vaccine development are expected to drive market growth.

The coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 has resulted in 399,600,607 cases and 5,757,562 deaths globally. COVID-19 is a severe hazard to human health around the world. The COVID-19 pandemic has been labeled a global public health emergency by the World Health Organization (WHO). Vaccination is the most successful and cost-efficient method for preventing the spread of the epidemic, saving lives and protecting population health. COVID-19 vaccines have been developed using a variety of ways. Among these, the COVID-19 messenger RNA (mRNA) vaccine has received increased attention due to its broad application potential and benefits, which include a short development cycle, ease of industrialization, a simple manufacturing process, the ability to respond to new variants, and the ability to induce a stronger immune response.

Moreover, researchers have long sought to use mRNA vaccines for cancer treatment. For nearly a decade, mRNA-based cancer therapy vaccines have been studied in modest studies, with some encouraging early findings. For instance, Pfizer-BioNTech and Moderna used their experience generating mRNA cancer vaccines to build coronavirus vaccines. Some researchers anticipate that the effectiveness of the mRNA COVID-19 vaccines may help advance clinical research on mRNA vaccines for cancer treatment. Thus, from the above statements, the market is expected to drive in the forecast period.

Restraint:

High costs associated with the miRNA kits are time-consuming, making the accurate computational prediction of miRNA targets a high priority; safety and toxicity issues of miRNA are some of the factors the market is expected to get hampered in the forecast period.

Industry Analysis

The microRNA market provides in-depth analysis of the market based on various industry factors such as supply chain analysis, pricing analysis etc.

COVID-19 Impact Analysis

The COVID-19 pandemic has moderately impacted healthcare systems and the market. miRNAs can inhibit the viral translation after the attachment of miRNAs to 3'-UTR of the viral genome or target the receptors, structural or nonstructural proteins of SARS-CoV-2 without affecting the expression of human genes. For instance, ID02510.3p-miRNA, ID00448.3pmiRNA, miRNA 3154, miRNA 7114-5p, miRNA 5197-3p, ID02750.3p-miRNA, and ID01851.5p-miRNA attenuate COVID-19 disease development by binding to the SARS-CoV-2 genome and inhibiting its post-transcriptional expression. Nersisyan et al. identified six miRNAs, including miR-21-3p, miR-195-5p, miR-16-5p, miR-3065-5p, miR-424-5p, and miR-421, that could regulate all human coronaviruses by binding directly to the viral genome. The best binding to the human coronavirus genome was found at miR-21-3p. Therefore, because of the increased COVID-19 infection, there is a greater need for effective therapy, which raises the demand for next-generation sequencing technologies and miRNA sequencing.

In contrast, the pandemic interrupts the supply chain and process. Many companies will vary to other geographic regions to ensure that products remain available and protect their supply chain. Thus, from the above statements, the market got affected, and it is expected to gain traction quickly with the resumption of economic activities.

Segment Analysis

Real Time Polymerase Chain Reaction segment is expected to hold the largest market share in microRNA market

The real-time polymerase chain reaction segment is expected to dominate in 2021. The segment benefits because it has a wide dynamic range, excellent sensitivity, can be very sequence-specific, requires little to no post-amplification processing, and can be scaled up to increase sample throughput. Moreover, the research of gene expression has been transformed by RT-PCR. The RNA transcript of any gene can now theoretically be detected, regardless of the scarcity of the starting material or the relative abundance of the specific mRNA. RT-PCR involves using a retroviral reverse transcriptase to copy an RNA template into complementary DNA (cDNA). PCR is then used to amplify the cDNA exponentially. RT-PCR, like NPAs, is fairly tolerant of degraded RNA. The target will be amplified if the RNA is intact inside the region spanned by the primers.

Moreover, Tata MD launched COVID express RT-PCR testing solutions in December 2021. Tata MD CHECK XF, a 3-Gene RT-PCR kit that does not require RNA extraction and uses a fast amplification procedure, is combined with a portable and quick qPCR analyzer and Tata MD CHECK RT-PCR Fast 3 Gene. Thus, from the above statements, the market segment is expected to hold the largest market share in the forecast period.

Geographical Analysis

North America region holds the largest market share in the global microRNA market

In 2021, North America accounted for the highest revenue share. The increasing prevalence of cancer and infectious diseases, rising demand for next-generation and microRNA services and applications in drug development, adoption of the latest technology, and established research infrastructure for proteomics, genomics, and oncology, rising patent approvals for their miRNA biomarkers and product launches by the key market players are some of the factors the market is expected to boost in the forecast period. For instance, in the United States, in 2019, 1,752,735 new cancer cases were reported, and 599,589 people died of cancer. For every 100,000 people, 439 new cancer cases were reported, and 146 people died of cancer. In contrast, In the United States, however, 2 million new cancer cases were identified in 2020, with 612,390 deaths. This shows that the cancer incidence and mortality rate are very high, increasing the demand for precision medications and therapies for patients and raising the demand for microRNA approaches in the region.

Moreover, On Oct. 21, 2021, Interpace Biosciences, Inc. announced that the United States Patent and Trademark Office granted it a Patent (US PTO Number 11,118,231 B2) for the use of microRNAs in the differentiation of benign from malignant thyroid neoplasms. This patent covers the technology that underpins its ThyraMIR microRNA Classifier. MicroRNAs are short non-coding RNAs that bind to messenger RNA and influence protein expression in human malignancies, including thyroid cancer. Thus, from the above statements, the North American region is expected to hold the largest market share in the forecast period.

Competitive Landscape

Major key players in the microRNA market are Qiagen N.V., Illumina, Inc., Takara Bio, Inc, PerkinElmer, Inc., Thermo Fisher Scientific, Bio-Rad Laboratories Inc., Abcam Plc, GeneCopoeia, Inc., System Biosciences LLC, Miltenyi Biotec.

Thermo Fisher Scientific:

Overview:

Thermo Fisher Scientific is an American company incorporated in 1956 and based in Waltham, Massachusetts. The company offers worldwide life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and services. Moreover, the global team has more than 90,000 colleagues who deliver an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon.

Product Portfolio:

TaqMan miRNA Assays: TaqMan MicroRNA Assays from Applied Biosystems quantify miRNAs using the specificity and sensitivity of TaqMan Assay chemistry. A straightforward two-step approach consists of reverse transcription using a miRNA-specific primer, followed by real-time PCR using TaqMan probes. TaqMan MicroRNA Assays are highly specific, sensitive, quick, easy to use, and scalable.

The global microRNA market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Advances in the COVID-19 mRNA vaccine development are expected to drive market growth.
    • 4.1.2. Restraints:
      • 4.1.2.1. High costs associated with the miRNA kits are expected to hamper the market growth.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Supply Chain Analysis
  • 5.2. Pricing Analysis
  • 5.3. Unmet Needs
  • 5.4. Pipeline Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Product

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 7.1.2. Market Attractiveness Index, By Product Segment
  • 7.2. Instruments & Kits*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Consumables
  • 7.4. Reagents
  • 7.5. Others

8. By Technology

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 8.1.2. Market Attractiveness Index, By Technology Segment
  • 8.2. Real Time Polymerase Chain Reaction*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Microarray
  • 8.4. Next Generation Sequencing (NGS)
  • 8.5. Immunoassay
  • 8.6. Others

9. By Application

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.1.2. Market Attractiveness Index, By Application Segment
  • 9.2. Cancer*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Infectious Diseases
  • 9.4. Immunological Disorder
  • 9.5. Cardiovascular Disease
  • 9.6. Neurological Disease
  • 9.7. Others

10. By End user

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.1.2. Market Attractiveness Index, By End user Segment
  • 10.2. Academic and Research Institutes*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Biopharmaceutical Companies
  • 10.4. Contract Research Organizations
  • 10.5. Diagnostic Centers
  • 10.6. Others

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user

12. Competitive Landscape

  • 12.1. Key Developments and Strategies
  • 12.2. Company Share Analysis
  • 12.3. Product Benchmarking
  • 12.4. List of Key Companies to Watch

13. Company Profiles

  • 13.1. Qiagen N.V.*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Illumina, Inc.
  • 13.3. Takara Bio, Inc
  • 13.4. PerkinElmer, Inc.
  • 13.5. Thermo Fisher Scientific
  • 13.6. Bio-Rad Laboratories Inc.
  • 13.7. Abcam Plc
  • 13.8. GeneCopoeia, Inc.
  • 13.9. System Biosciences LLC
  • 13.10. Miltenyi Biotec

LIST NOT EXHAUSTIVE

14. Global MicroRNA Market - DataM

  • 14.1. Appendix
  • 14.2. About Us and Applications
  • 14.3. Contact Us